<p>Bio-Techne（纳斯达克代码：TECH - 获取免费报告）在周四的报告中被 Leerink Partners 的股票分析师从 “强力买入” 评级下调至 “持有” 评级，Zacks.com 报道。</p>
<ul>
<li>Bio-Techne、J2 Global 和 InMode 突破底部，接近买入点</li>
</ul>
<p>其他分析师也对该股票发布了报告。德意志银行将 Bio-Techne 的股票评级从 “买入” 下调至 “持有”，并设定了 73.00 美元的目标价。在 6 月 8 日的研究报告中，Zacks Research 将 Bio-Techne 的评级从 “持有” 下调至 “强烈卖出”。William Blair 在周四的研究报告中将 Bio-Techne 的股票评级从 “跑赢大盘” 下调至 “市场表现”。Piper Sandler 在 6 月 11 日的报告中开始覆盖 Bio-Techne 的股票，给予 “中性” 评级和 65.00 美元的目标价。最后，TD Cowen 在周二的研究报告中重申了 Bio-Techne 的 “买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，八位给予 “买入” 评级，六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 65.79 美元。</p>
<p><strong>查看我们最新的研究报告关于 TECH</strong></p>
<h2>Bio-Techne 股票表现</h2>
<p>周四，TECH 的股票开盘价为 70.70 美元。该公司的市值为 110.7 亿美元，市盈率为 102.47，市盈增长比率为 5.67，贝塔值为 1.37。该公司的速动比率为 3.18，流动比率为 4.49，债务股本比率为 0.10。该公司的 50 日简单移动平均为 52.70 美元，200 日简单移动平均为 56.99 美元。Bio-Techne 的 52 周低点为 43.19 美元，52 周高点为 72.16 美元。</p>
<p>Bio-Techne（纳斯达克代码：TECH - 获取免费报告）最后一次发布财报是在 5 月 6 日，生物技术公司报告季度每股收益为 0.53 美元，低于分析师一致预期的 0.55 美元（差额为 0.02 美元）。Bio-Techne 的股本回报率为 13.57%，净利润率为 9.05%。该公司季度收入为 3.1142 亿美元，而分析师预期为 3.1611 亿美元。在去年同期，该公司每股收益为 0.56 美元。与去年同期相比，该公司的季度收入下降了 1.5%。股票研究分析师预测 Bio-Techne 在当前财年将发布 1.66 美元的每股收益。</p>
<h2>对 Bio-Techne 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近买入和卖出了该股票的股份。NewEdge Advisors LLC 在第一季度将其在 Bio-Techne 的持仓增加了 15,993.8%。NewEdge Advisors LLC 目前拥有 7,725 股生物技术公司的股票，价值 404,000 美元，此前在上个季度增持了 7,677 股。Henshaw Capital LLC 在第一季度将其在 Bio-Techne 的股份增加了 31.2%。Henshaw Capital LLC 目前拥有 45,905 股生物技术公司的股票，价值 2,399,000 美元，此前在此期间增持了 10,915 股。Summitry LLC 在第一季度将其在 Bio-Techne 的持仓增加了 17.1%。Summitry LLC 目前拥有 6,013 股生物技术公司的股票，价值 314,000 美元，此前在上个季度增持了 879 股。Intrinsic Edge Capital Management LLC 在第一季度购买了 Bio-Techne 的新头寸，价值约为 5,749,000 美元。最后，Edgestream Partners L.P.在第一季度购买了 Bio-Techne 的新头寸，价值约为 292,000 美元。98.95% 的股票由机构投资者和对冲基金持有。</p>
<h2>影响 Bio-Techne 的关键头条</h2>
<p>以下是本周影响 Bio-Techne 的关键新闻：</p>
<ul>
<li>积极情绪：默克 KGaA 同意以每股 73 美元的现金收购 Bio-Techne，为股东提供明确的退出价值，并可能推动股票接近交易价格。德国达姆施塔特的默克同意收购 Bio-Techne</li>
<li>积极情绪：该报价相对于 Bio-Techne 最近的股价具有相当大的溢价，通常会提升收购目标股票的价格，因为投资者会考虑交易完成。德国默克以每股 73 美元收购 Bio-Techne</li>
<li>中性情绪：多家律师事务所宣布对股东进行调查，以确定 Bio-Techne 的董事会是否获得了公平价格，这可能会产生法律噪音，但不会改变已宣布的交易条款。股东警报：Ademi LLP 调查 Bio-Techne 公司是否为公众股东获得公平价格</li>
<li>中性情绪：报告的空头头寸数据显示没有显著的空头头寸，因此这一举动似乎更多是由收购公告驱动，而非空头回补。Bio-Techne 因每股 73 美元的现金收购协议而激增</li>
</ul>
<h2>关于 Bio-Techne</h2>
<p>（获取免费报告）</p>
<p>Bio-Techne Corporation（纳斯达克：TECH）是一家全球生命科学公司，开发、制造和销售高质量的试剂、仪器和服务，面向研究、诊断和生物加工市场。其核心产品包括重组蛋白、抗体、免疫测定、核酸探针和试剂盒、单细胞分析解决方案以及自动化蛋白分析系统。R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 等旗舰品牌为研究人员和临床医生提供可靠的细胞生物学、免疫学、蛋白质组学和基因组学应用工具。</p>
<p>Bio-Techne 总部位于明尼阿波利斯，明尼苏达州，通过直接销售、分销商和战略合作伙伴关系为北美、欧洲和亚太地区的客户提供服务。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Bio-Techne</li>
<li>黑莓的反弹不仅仅依赖于盈利，更是一个更大的人工智能故事</li>
<li>MDA Space 以 6.2 亿美元收购目标美国国防市场</li>
<li>嘉年华的第二季度：这只股票仍然复杂吗？</li>
<li>多米诺的股票因投资者消化 CEO 更换而跌至 52 周低点</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bio-Techne 吗？</h2>
<p>在考虑 Bio-Techne 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Bio-Techne 并不在名单上。</p>
<p>虽然 Bio-Techne 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TECH

德国默克

<p>Leerink Partners 将 Bio-Techne（NASDAQ:TECH）的评级从 “强烈买入” 下调至 “持有”。其他分析师也调整了评级，德意志银行和威廉·布莱尔将评级调整为 “持有”，Zacks 调整为 “强烈卖出”，而派珀·桑德勒则首次给予 “中性” 评级。TD Cowen 重申 “买入” 评级。该股票目前交易价格接近 70.70 美元，市场共识目标为 65.79 美元。默克集团同意以每股 73 美元的现金收购 Bio-Techne</p>

<p>Bio-Techne (NASDAQ:TECH - Get Free Report) was downgraded by stock analysts at Leerink Partners from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Bio-Techne（纳斯达克代码：TECH - 获取免费报告）在周四的报告中被 Leerink Partners 的股票分析师从 “强力买入” 评级下调至 “持有” 评级，Zacks.com 报道。</p>
</div><ul>
<li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li>
</ul>
<div class="lb-trans"><ul>
<li>Bio-Techne、J2 Global 和 InMode 突破底部，接近买入点</li>
</ul>
</div><p>Other analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft lowered shares of Bio-Techne from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $73.00 price target on the stock. in a research report on Friday. Zacks Research lowered Bio-Techne from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, June 8th. William Blair downgraded shares of Bio-Techne from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research note on Thursday. Piper Sandler initiated coverage on shares of Bio-Techne in a report on Thursday, June 11th. They issued a &#34;neutral&#34; rating and a $65.00 target price on the stock. Finally, TD Cowen reaffirmed a &#34;buy&#34; rating on shares of Bio-Techne in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $65.79.</p>
<div class="lb-trans"><p>其他分析师也对该股票发布了报告。德意志银行将 Bio-Techne 的股票评级从 “买入” 下调至 “持有”，并设定了 73.00 美元的目标价。在 6 月 8 日的研究报告中，Zacks Research 将 Bio-Techne 的评级从 “持有” 下调至 “强烈卖出”。William Blair 在周四的研究报告中将 Bio-Techne 的股票评级从 “跑赢大盘” 下调至 “市场表现”。Piper Sandler 在 6 月 11 日的报告中开始覆盖 Bio-Techne 的股票，给予 “中性” 评级和 65.00 美元的目标价。最后，TD Cowen 在周二的研究报告中重申了 Bio-Techne 的 “买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，八位给予 “买入” 评级，六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 65.79 美元。</p>
</div><p><strong>View Our Latest Research Report on TECH</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的研究报告关于 TECH</strong></p>
</div><h2>Bio-Techne Stock Performance</h2>
<div class="lb-trans"><h2>Bio-Techne 股票表现</h2>
</div><p>Shares of TECH opened at $70.70 on Thursday. The company has a market capitalization of $11.07 billion, a PE ratio of 102.47, a P/E/G ratio of 5.67 and a beta of 1.37. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The company has a 50-day simple moving average of $52.70 and a 200-day simple moving average of $56.99. Bio-Techne has a 52-week low of $43.19 and a 52-week high of $72.16.</p>
<div class="lb-trans"><p>周四，TECH 的股票开盘价为 70.70 美元。该公司的市值为 110.7 亿美元，市盈率为 102.47，市盈增长比率为 5.67，贝塔值为 1.37。该公司的速动比率为 3.18，流动比率为 4.49，债务股本比率为 0.10。该公司的 50 日简单移动平均为 52.70 美元，200 日简单移动平均为 56.99 美元。Bio-Techne 的 52 周低点为 43.19 美元，52 周高点为 72.16 美元。</p>
</div><p>Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The firm had revenue of $311.42 million for the quarter, compared to analysts' expectations of $316.11 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The firm's revenue for the quarter was down 1.5% compared to the same quarter last year. Equities research analysts predict that Bio-Techne will post 1.66 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bio-Techne（纳斯达克代码：TECH - 获取免费报告）最后一次发布财报是在 5 月 6 日，生物技术公司报告季度每股收益为 0.53 美元，低于分析师一致预期的 0.55 美元（差额为 0.02 美元）。Bio-Techne 的股本回报率为 13.57%，净利润率为 9.05%。该公司季度收入为 3.1142 亿美元，而分析师预期为 3.1611 亿美元。在去年同期，该公司每股收益为 0.56 美元。与去年同期相比，该公司的季度收入下降了 1.5%。股票研究分析师预测 Bio-Techne 在当前财年将发布 1.66 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Bio-Techne</h2>
<div class="lb-trans"><h2>对 Bio-Techne 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its position in Bio-Techne by 15,993.8% in the first quarter. NewEdge Advisors LLC now owns 7,725 shares of the biotechnology company's stock valued at $404,000 after acquiring an additional 7,677 shares in the last quarter. Henshaw Capital LLC increased its stake in Bio-Techne by 31.2% during the 1st quarter. Henshaw Capital LLC now owns 45,905 shares of the biotechnology company's stock worth $2,399,000 after buying an additional 10,915 shares during the period. Summitry LLC lifted its holdings in Bio-Techne by 17.1% in the 1st quarter. Summitry LLC now owns 6,013 shares of the biotechnology company's stock worth $314,000 after buying an additional 879 shares in the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in Bio-Techne in the 1st quarter valued at about $5,749,000. Finally, Edgestream Partners L.P. purchased a new position in Bio-Techne in the 1st quarter valued at about $292,000. 98.95% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了该股票的股份。NewEdge Advisors LLC 在第一季度将其在 Bio-Techne 的持仓增加了 15,993.8%。NewEdge Advisors LLC 目前拥有 7,725 股生物技术公司的股票，价值 404,000 美元，此前在上个季度增持了 7,677 股。Henshaw Capital LLC 在第一季度将其在 Bio-Techne 的股份增加了 31.2%。Henshaw Capital LLC 目前拥有 45,905 股生物技术公司的股票，价值 2,399,000 美元，此前在此期间增持了 10,915 股。Summitry LLC 在第一季度将其在 Bio-Techne 的持仓增加了 17.1%。Summitry LLC 目前拥有 6,013 股生物技术公司的股票，价值 314,000 美元，此前在上个季度增持了 879 股。Intrinsic Edge Capital Management LLC 在第一季度购买了 Bio-Techne 的新头寸，价值约为 5,749,000 美元。最后，Edgestream Partners L.P.在第一季度购买了 Bio-Techne 的新头寸，价值约为 292,000 美元。98.95% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Key Headlines Impacting Bio-Techne</h2>
<div class="lb-trans"><h2>影响 Bio-Techne 的关键头条</h2>
</div><p>Here are the key news stories impacting Bio-Techne this week:</p>
<div class="lb-trans"><p>以下是本周影响 Bio-Techne 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, giving shareholders a clear exit value and likely driving the stock toward the deal price. Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne</li>
<li>Positive Sentiment: The offer represents a sizable premium to Bio-Techne’s recent share price, which typically boosts takeover-target stocks as investors price in deal completion. Germany's Merck to buy Bio-Techne for $73 per share</li>
<li>Neutral Sentiment: Multiple law firms announced shareholder investigations into whether Bio-Techne’s board secured a fair price, which could create legal noise but does not change the announced deal terms. Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders</li>
<li>Neutral Sentiment: Reported short-interest data showed no meaningful short position, so the move appears driven more by the takeover announcement than by short covering. Bio-Techne Surges on $73-Per-Share Cash Takeover Agreement</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：默克 KGaA 同意以每股 73 美元的现金收购 Bio-Techne，为股东提供明确的退出价值，并可能推动股票接近交易价格。德国达姆施塔特的默克同意收购 Bio-Techne</li>
<li>积极情绪：该报价相对于 Bio-Techne 最近的股价具有相当大的溢价，通常会提升收购目标股票的价格，因为投资者会考虑交易完成。德国默克以每股 73 美元收购 Bio-Techne</li>
<li>中性情绪：多家律师事务所宣布对股东进行调查，以确定 Bio-Techne 的董事会是否获得了公平价格，这可能会产生法律噪音，但不会改变已宣布的交易条款。股东警报：Ademi LLP 调查 Bio-Techne 公司是否为公众股东获得公平价格</li>
<li>中性情绪：报告的空头头寸数据显示没有显著的空头头寸，因此这一举动似乎更多是由收购公告驱动，而非空头回补。Bio-Techne 因每股 73 美元的现金收购协议而激增</li>
</ul>
</div><h2>About Bio-Techne</h2>
<div class="lb-trans"><h2>关于 Bio-Techne</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&amp;D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.</p>
<div class="lb-trans"><p>Bio-Techne Corporation（纳斯达克：TECH）是一家全球生命科学公司，开发、制造和销售高质量的试剂、仪器和服务，面向研究、诊断和生物加工市场。其核心产品包括重组蛋白、抗体、免疫测定、核酸探针和试剂盒、单细胞分析解决方案以及自动化蛋白分析系统。R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 等旗舰品牌为研究人员和临床医生提供可靠的细胞生物学、免疫学、蛋白质组学和基因组学应用工具。</p>
</div><p>Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.</p>
<div class="lb-trans"><p>Bio-Techne 总部位于明尼阿波利斯，明尼苏达州，通过直接销售、分销商和战略合作伙伴关系为北美、欧洲和亚太地区的客户提供服务。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Bio-Techne</li>
<li>BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone</li>
<li>MDA Space Targets US Defense Market With $620M Acquisition</li>
<li>Carnival's Second Quarter: Is the Stock Still Complicated?</li>
<li>Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Bio-Techne</li>
<li>黑莓的反弹不仅仅依赖于盈利，更是一个更大的人工智能故事</li>
<li>MDA Space 以 6.2 亿美元收购目标美国国防市场</li>
<li>嘉年华的第二季度：这只股票仍然复杂吗？</li>
<li>多米诺的股票因投资者消化 CEO 更换而跌至 52 周低点</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TECH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bio-Techne 吗？</h2>
</div><p>Before you consider Bio-Techne, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Bio-Techne 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Bio-Techne 并不在名单上。</p>
</div><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bio-Techne 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bio-Techne (NASDAQ:TECH) Cut to "Hold" at Leerink Partners

Market Beat

Bio-Techne（NASDAQ:TECH）在 Leerink Partners 被下调至 “持有” 评级